Global Amniotic Products Market Overview
Global Amniotic Products Market was valued at USD 881.55 Million in 2023 and is expected to reach USD 1580.25 Million by the year 2032, at a CAGR of 6.7%.
The amniotic products market is located in regenerative medicine and utilizes the special characteristics of amniotic membranes, which are stored in cryopreserved or dehydrated form for different medical uses. Most commonly used in wound care, ophthalmology, and orthopedics, these membranes demonstrate anti-inflammatory and wound-healing capabilities. Hospitals and surgical centers are currently at the forefront in their utilization, but an increase appears to be on the horizon. Causes driving market expansion include the need for cutting-edge wound healing options, the discovery of fresh ophthalmic uses, and the increasing incidence of long-term illnesses. Supportive regulatory environments, particularly in areas such as China and India, also contribute to promoting innovation and expanding markets. Staying updated on advancements by monitoring new application research, tracking clinical trials, and following industry publications is crucial.
The studies on the advantages and potency of amniotic tissue in wounds date back over 100 years. Therefore, these characteristics make amniotic allografts an attractive wound biomaterial. Amniotic fluid allograft is a product that contained human amniotic membrane and amniotic fluid components obtained from the placental tissue of consenting mothers at the time of a live, full-term elective Cesarean birth. In recent years, Amniotic Products s research has developed treatments for a myriad of orthopedic conditions, incorporating osteoarthritis and plantar fasciitis. Moreover, it is being analyzed as a treatment for several other musculoskeletal conditions. The growing number of traumatic wounds and the growth in ophthalmology, orthopedic, and cosmetic surgeries will have an extreme impact on the growth of the market of Amniotic Products.
Market Dynamics And Factors For The Amniotic Products Market
Drivers:
An increasing prevalence of burn injuries to seeking for significant growth for Amniotic Products s market. Cases related to burn wounds and injuries have increased highly over the years. As the World Health Organization (WHO) states that nearly 180000 deaths are caused owing to burns every year. The statistics by the WHO further highlight that more than 1000000 people are moderately or adversely burnt every year. These statistics shed light on the requirement for treatment to decline the effect of the wounds. As Amniotic Products s are used for healing such wounds, the demand is anticipated to increase.
Additionally, as per the WHO, a majority of burn cases arise in low- and middle-income countries, and almost two-thirds occur in the WHO African and Southeast Asian regions. For example, in India, 1 million people bear moderate and adverse burns every year (Source: WHO). The prevalence of burns is also high in other Southeast Asian countries such as Bangladesh and Nepal. Furthermore, the execution of acts and various government initiatives to stimulate regenerative medicine research brings significant Amniotic Products market growth opportunities. Many economies are targeting improving research in regenerative medicine. This aspect may have a great impact on the expansion of the Amniotic Products market during the forecast period. Fast-track approvals for novel regenerative medicine products and other factors are also looked upon by launching various acts and initiatives. Therefore, these factors will bring major Amniotic Products market growth prospects.
Restraints:
Amniotic membranes are not to be utilized arbitrarily since there could be an occasional risk of complications. The patient or the recipient of an amniotic membrane could transmit bacterial, viral, or fungal infections if the donors are not acceptably screened for communicable diseases. Other risks to the patient/recipient may also occur if the membrane is not processed under sterile conditions, or if the membrane is inappropriately stored. Incidence rates of 1.6% to 8.0% have been recorded post amniotic membrane transplantation, with gram-positive isolates being registered most frequently. Also, premature degradation of an amniotic membrane and cheese wiring may further lead to frequent and repetitive transplantations, which in itself is a risk.
Opportunities:
Increasing government support for regenerative medicine research
Increased government support for regenerative medicine research presents a significant opportunity for the amniotic products market. This funding boost will accelerate research into the therapeutic applications of amniotic tissues. Government grants can fund clinical trials that explore the effectiveness of amniotic membrane products in treating a wider range of conditions. This could include anything from chronic wounds and burns to neurological disorders and organ failure. Positive results from these trials will build stronger scientific evidence for the use of amniotic products, leading to wider adoption by healthcare professionals.
Increased government investment can streamline regulations and create a more favorable environment for the development and commercialization of amniotic products. This could involve simplifying the approval process for new amniotic-based therapies or providing financial incentives for companies to invest in research and manufacturing. With smoother regulations and potential tax breaks, companies will be more likely to enter the amniotic products market, leading to a wider variety of products and potentially lower costs for patients. This overall growth in the regenerative medicine field, fueled by government support, will directly translate to a larger and more lucrative market for amniotic products.
Scope of the Amniotic Products Market
The main goal of this report is to help users understand the Amniotic Products market in terms of its definition, segmentation, market potential, influential trends, and challenges facing the market. In-depth research and analysis took place while preparing the report. Readers will find this report very helpful to in-depth understanding of the market.
Market Segmentation
Segmentation Analysis of Amniotic Products Market:
Based on the Type, the amniotic membrane segment is expected to register the highest Amniotic Products s market share over the forecast period. The maximum share of this segment can be attributed to its increased usage in several procedures and amniotic membranes are more effective than amniotic suspensions. Amniotic membrane has different antimicrobial and biological properties in corneal surgery, as it improves epithelialization, reinforces adhesion of basal epithelial cells, maintains epithelial phenotype, and modulates the proliferation of normal corneal, conjunctival, and limbal fibroblast. These membranes are also a defense against apoptosis, as well as inflammation, inhibit scarring, and neovascularization.
Based on Application, the wound care segment is expected to dominate the market of Amniotic Products s over the forecast period. Owing to the rising incidence of ulcers, traumatic and surgical wounds, and burns, and the requirement for advanced technologies for treatment. Amniotic Products s may be utilized for wounds that are chronic and non-healing. Furthermore, the human amniotic membrane has been utilized to treat different types of wounds for over 100 years. Research has shown that placental tissues can promote angiogenesis and new tissue formation, overcome scar tissue formation, modulate inflammation and pain, and may have anti-microbial effects.
Based on End-Users, the ambulatory surgery centers (ASCs) segment is expected to hold a larger Amniotic Products s market share in the forecast period. The growth of the market of Amniotic Products s is attributed to the rising demand for wound care biologics such as amniotic tissue products in hospitals and ASCs. In addition, rising incidence of hospital-acquired pressure ulcers, the growing number of adverse burn cases and rising consciousness regarding advanced burn care treatment, and the availability of reimbursement.
Regional Analysis of Amniotic Products Market:
North America dominates the global amniotic products market, driven by its advanced healthcare infrastructure, favorable reimbursement policies, high adoption of advanced therapies, and growing demand for specialized care due to an aging population. With well-established hospitals, clinics, and research institutions, the region facilitates the development and implementation of amniotic product technologies. Government and private insurance programs often cover costs, enhancing accessibility. The region's healthcare providers are early adopters of cutting-edge medical technologies, making amniotic products, with their potential for wound healing and tissue regeneration, particularly appealing. Looking ahead, researchers are exploring new frontiers in regenerative medicine, envisioning applications in tissue regeneration, skin grafts, burn repair, organ regeneration, and stem cell therapy, leveraging the rich source of stem cells found in amniotic fluid.
Players Covered in Amniotic Products Market are :
- LifeCell International Pvt. Ltd. (India)
- Applied Biologics (US)
- Lucina BioSciences (US)
- Skye Biologics Holdings
- LLC (US)
- Nuvision Biotherapies Limited (UK)
- AlloSource (US)
- MiMedx (US)
- Surgilogix (US)
- Smith & Nephew (UK)
- Organogenesis Inc. (US)
- Integra Lifesciences Corporation (US)
- Stryker (US)
- Next Biosciences (South Africa)
- Celularity
- Inc. (the US)
- NuVision Biotherapies Ltd. (UK)
- Katena Products
- Inc. (US)
- Surgenex (US)
- TissueTech
- Inc. (the US)
- Ventris Medical
- LLC (US)
- StimLabs LLC (US)
- VIVEX Biologics
- Inc. (the US)
- Genesis Biologics (US)
- Tides Medical (US)
- Orthofix Medical Inc. (US)
- Merakris Therapeutics (US)
- MTF Biologics (US) and others major players.
Key Industry Developments In The Amniotic Products Market
- In 2021, MiMedx (US) obtained approval from the Japanese Ministry of Health, Labour, and Welfare for the commercialization of EPIFIX in Japan.
- In 2021, Organogenesis Inc. (US) introduced ReNu an amniotic suspension, the company also obtained approval from the US FDA by granting the Regenerative Medicine Advanced Therapy designation for application in knee osteoarthritis.
- In February 2022, Amnio Technology unveiled two groundbreaking additions to its lineup of amniotic tissue allografts, PalinGen® Dual-Layer Membrane and Dual Layer PalinGen® X-Membrane. These FDA-recognized products boast minimal manipulation, homologous use, and chorion-free composition. With their unique dual-layered design, these allografts offer enhanced durability and slower resorption, making them well-suited for diverse applications in wound management and surgical procedures. Senior Director of New Product Development, Robert Diller, PhD, highlighted the strategic focus on improving efficacy in complex surgical settings.
- In April 2022, Sanara MedTech Inc. revealed its acquisition of Precision Healing Inc., marking a significant move in the competitive landscape of the amniotic products market. Sanara's merger with Precision Healing, a pioneer in chronic wound diagnosis technologies, is poised to revolutionize patient care. Ron Nixon, Sanara's Executive Chairman, expressed optimism about Precision Healing's multispectral imager and biomarker assay, anticipating improved diagnosis and treatment outcomes for chronic wounds, aligning with the growing demand for advanced wound care solutions.
|
Global Amniotic Products Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2032 |
Market Size in 2023: |
USD 881.55 Mn. |
|
Forecast Period 2024-32 CAGR: |
6.7% |
Market Size in 2032: |
USD 1580.25 Mn. |
|
Segments Covered: |
By Type |
|
|
|
By Application |
|
||
|
By End-User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
3.3 By End-User
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Amniotic Products Market by Type
5.1 Amniotic Products Market Overview Snapshot and Growth Engine
5.2 Amniotic Products Market Overview
5.3 Amniotic Membranes {Cryopreserved
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Amniotic Membranes {Cryopreserved: Grographic Segmentation
5.4 Dehydrated}
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Dehydrated}: Grographic Segmentation
5.5 Amniotic Suspensions
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2028F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Amniotic Suspensions: Grographic Segmentation
Chapter 6: Amniotic Products Market by Application
6.1 Amniotic Products Market Overview Snapshot and Growth Engine
6.2 Amniotic Products Market Overview
6.3 Wound Care
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Wound Care: Grographic Segmentation
6.4 Ophthalmology
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Ophthalmology: Grographic Segmentation
6.5 Orthopedics
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Orthopedics: Grographic Segmentation
6.6 Other
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2016-2028F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Other: Grographic Segmentation
Chapter 7: Amniotic Products Market by End-User
7.1 Amniotic Products Market Overview Snapshot and Growth Engine
7.2 Amniotic Products Market Overview
7.3 Hospitals
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size (2016-2028F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 Hospitals: Grographic Segmentation
7.4 ASCs
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size (2016-2028F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 ASCs: Grographic Segmentation
7.5 Others
7.5.1 Introduction and Market Overview
7.5.2 Historic and Forecasted Market Size (2016-2028F)
7.5.3 Key Market Trends, Growth Factors and Opportunities
7.5.4 Others: Grographic Segmentation
Chapter 8: Company Profiles and Competitive Analysis
8.1 Competitive Landscape
8.1.1 Competitive Positioning
8.1.2 Amniotic Products Sales and Market Share By Players
8.1.3 Industry BCG Matrix
8.1.4 Ansoff Matrix
8.1.5 Amniotic Products Industry Concentration Ratio (CR5 and HHI)
8.1.6 Top 5 Amniotic Products Players Market Share
8.1.7 Mergers and Acquisitions
8.1.8 Business Strategies By Top Players
8.2 LIFECELL INTERNATIONAL PVT. LTD.
8.2.1 Company Overview
8.2.2 Key Executives
8.2.3 Company Snapshot
8.2.4 Operating Business Segments
8.2.5 Product Portfolio
8.2.6 Business Performance
8.2.7 Key Strategic Moves and Recent Developments
8.2.8 SWOT Analysis
8.3 APPLIED BIOLOGICS
8.4 LUCINA BIOSCIENCES
8.5 SKYE BIOLOGICS HOLDINGS LLC
8.6 NUVISION BIOTHERAPIES LIMITED
8.7 ALLOSOURCE
8.8 MIMEDX
8.9 SURGILOGIX
8.10 SMITH & NEPHEW
8.11 ORGANOGENESIS INC.
8.12 INTEGRA LIFESCIENCES CORPORATION
8.13 STRYKER
8.14 NEXT BIOSCIENCES
8.15 CELULARITY INC.
8.16 NUVISION BIOTHERAPIES LTD.
8.17 KATENA PRODUCTS INC.
8.18 SURGENEX
8.19 TISSUETECH INC.
8.20 VENTRIS MEDICAL LLC
8.21 STIMLABS LLC
8.22 VIVEX BIOLOGICS INC
8.23 GENESIS BIOLOGICS
8.24 TIDES MEDICAL
8.25 ORTHOFIX MEDICAL INC.
8.26 MERAKRIS THERAPEUTICS
8.27 MTF BIOLOGICS
8.28 OTHER MAJOR PLAYERS
Chapter 9: Global Amniotic Products Market Analysis, Insights and Forecast, 2016-2028
9.1 Market Overview
9.2 Historic and Forecasted Market Size By Type
9.2.1 Amniotic Membranes {Cryopreserved
9.2.2 Dehydrated}
9.2.3 Amniotic Suspensions
9.3 Historic and Forecasted Market Size By Application
9.3.1 Wound Care
9.3.2 Ophthalmology
9.3.3 Orthopedics
9.3.4 Other
9.4 Historic and Forecasted Market Size By End-User
9.4.1 Hospitals
9.4.2 ASCs
9.4.3 Others
Chapter 10: North America Amniotic Products Market Analysis, Insights and Forecast, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Amniotic Membranes {Cryopreserved
10.4.2 Dehydrated}
10.4.3 Amniotic Suspensions
10.5 Historic and Forecasted Market Size By Application
10.5.1 Wound Care
10.5.2 Ophthalmology
10.5.3 Orthopedics
10.5.4 Other
10.6 Historic and Forecasted Market Size By End-User
10.6.1 Hospitals
10.6.2 ASCs
10.6.3 Others
10.7 Historic and Forecast Market Size by Country
10.7.1 U.S.
10.7.2 Canada
10.7.3 Mexico
Chapter 11: Europe Amniotic Products Market Analysis, Insights and Forecast, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Amniotic Membranes {Cryopreserved
11.4.2 Dehydrated}
11.4.3 Amniotic Suspensions
11.5 Historic and Forecasted Market Size By Application
11.5.1 Wound Care
11.5.2 Ophthalmology
11.5.3 Orthopedics
11.5.4 Other
11.6 Historic and Forecasted Market Size By End-User
11.6.1 Hospitals
11.6.2 ASCs
11.6.3 Others
11.7 Historic and Forecast Market Size by Country
11.7.1 Germany
11.7.2 U.K.
11.7.3 France
11.7.4 Italy
11.7.5 Russia
11.7.6 Spain
11.7.7 Rest of Europe
Chapter 12: Asia-Pacific Amniotic Products Market Analysis, Insights and Forecast, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Amniotic Membranes {Cryopreserved
12.4.2 Dehydrated}
12.4.3 Amniotic Suspensions
12.5 Historic and Forecasted Market Size By Application
12.5.1 Wound Care
12.5.2 Ophthalmology
12.5.3 Orthopedics
12.5.4 Other
12.6 Historic and Forecasted Market Size By End-User
12.6.1 Hospitals
12.6.2 ASCs
12.6.3 Others
12.7 Historic and Forecast Market Size by Country
12.7.1 China
12.7.2 India
12.7.3 Japan
12.7.4 Singapore
12.7.5 Australia
12.7.6 New Zealand
12.7.7 Rest of APAC
Chapter 13: Middle East & Africa Amniotic Products Market Analysis, Insights and Forecast, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Amniotic Membranes {Cryopreserved
13.4.2 Dehydrated}
13.4.3 Amniotic Suspensions
13.5 Historic and Forecasted Market Size By Application
13.5.1 Wound Care
13.5.2 Ophthalmology
13.5.3 Orthopedics
13.5.4 Other
13.6 Historic and Forecasted Market Size By End-User
13.6.1 Hospitals
13.6.2 ASCs
13.6.3 Others
13.7 Historic and Forecast Market Size by Country
13.7.1 Turkey
13.7.2 Saudi Arabia
13.7.3 Iran
13.7.4 UAE
13.7.5 Africa
13.7.6 Rest of MEA
Chapter 14: South America Amniotic Products Market Analysis, Insights and Forecast, 2016-2028
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Amniotic Membranes {Cryopreserved
14.4.2 Dehydrated}
14.4.3 Amniotic Suspensions
14.5 Historic and Forecasted Market Size By Application
14.5.1 Wound Care
14.5.2 Ophthalmology
14.5.3 Orthopedics
14.5.4 Other
14.6 Historic and Forecasted Market Size By End-User
14.6.1 Hospitals
14.6.2 ASCs
14.6.3 Others
14.7 Historic and Forecast Market Size by Country
14.7.1 Brazil
14.7.2 Argentina
14.7.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
|
Global Amniotic Products Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2032 |
Market Size in 2023: |
USD 881.55 Mn. |
|
Forecast Period 2024-32 CAGR: |
6.7% |
Market Size in 2032: |
USD 1580.25 Mn. |
|
Segments Covered: |
By Type |
|
|
|
By Application |
|
||
|
By End-User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
LIST OF TABLES
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. AMNIOTIC PRODUCTS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. AMNIOTIC PRODUCTS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. AMNIOTIC PRODUCTS MARKET COMPETITIVE RIVALRY
TABLE 005. AMNIOTIC PRODUCTS MARKET THREAT OF NEW ENTRANTS
TABLE 006. AMNIOTIC PRODUCTS MARKET THREAT OF SUBSTITUTES
TABLE 007. AMNIOTIC PRODUCTS MARKET BY TYPE
TABLE 008. AMNIOTIC MEMBRANES {CRYOPRESERVED MARKET OVERVIEW (2016-2028)
TABLE 009. DEHYDRATED} MARKET OVERVIEW (2016-2028)
TABLE 010. AMNIOTIC SUSPENSIONS MARKET OVERVIEW (2016-2028)
TABLE 011. AMNIOTIC PRODUCTS MARKET BY APPLICATION
TABLE 012. WOUND CARE MARKET OVERVIEW (2016-2028)
TABLE 013. OPHTHALMOLOGY MARKET OVERVIEW (2016-2028)
TABLE 014. ORTHOPEDICS MARKET OVERVIEW (2016-2028)
TABLE 015. OTHER MARKET OVERVIEW (2016-2028)
TABLE 016. AMNIOTIC PRODUCTS MARKET BY END-USER
TABLE 017. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 018. ASCS MARKET OVERVIEW (2016-2028)
TABLE 019. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 020. NORTH AMERICA AMNIOTIC PRODUCTS MARKET, BY TYPE (2016-2028)
TABLE 021. NORTH AMERICA AMNIOTIC PRODUCTS MARKET, BY APPLICATION (2016-2028)
TABLE 022. NORTH AMERICA AMNIOTIC PRODUCTS MARKET, BY END-USER (2016-2028)
TABLE 023. N AMNIOTIC PRODUCTS MARKET, BY COUNTRY (2016-2028)
TABLE 024. EUROPE AMNIOTIC PRODUCTS MARKET, BY TYPE (2016-2028)
TABLE 025. EUROPE AMNIOTIC PRODUCTS MARKET, BY APPLICATION (2016-2028)
TABLE 026. EUROPE AMNIOTIC PRODUCTS MARKET, BY END-USER (2016-2028)
TABLE 027. AMNIOTIC PRODUCTS MARKET, BY COUNTRY (2016-2028)
TABLE 028. ASIA PACIFIC AMNIOTIC PRODUCTS MARKET, BY TYPE (2016-2028)
TABLE 029. ASIA PACIFIC AMNIOTIC PRODUCTS MARKET, BY APPLICATION (2016-2028)
TABLE 030. ASIA PACIFIC AMNIOTIC PRODUCTS MARKET, BY END-USER (2016-2028)
TABLE 031. AMNIOTIC PRODUCTS MARKET, BY COUNTRY (2016-2028)
TABLE 032. MIDDLE EAST & AFRICA AMNIOTIC PRODUCTS MARKET, BY TYPE (2016-2028)
TABLE 033. MIDDLE EAST & AFRICA AMNIOTIC PRODUCTS MARKET, BY APPLICATION (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA AMNIOTIC PRODUCTS MARKET, BY END-USER (2016-2028)
TABLE 035. AMNIOTIC PRODUCTS MARKET, BY COUNTRY (2016-2028)
TABLE 036. SOUTH AMERICA AMNIOTIC PRODUCTS MARKET, BY TYPE (2016-2028)
TABLE 037. SOUTH AMERICA AMNIOTIC PRODUCTS MARKET, BY APPLICATION (2016-2028)
TABLE 038. SOUTH AMERICA AMNIOTIC PRODUCTS MARKET, BY END-USER (2016-2028)
TABLE 039. AMNIOTIC PRODUCTS MARKET, BY COUNTRY (2016-2028)
TABLE 040. LIFECELL INTERNATIONAL PVT. LTD.: SNAPSHOT
TABLE 041. LIFECELL INTERNATIONAL PVT. LTD.: BUSINESS PERFORMANCE
TABLE 042. LIFECELL INTERNATIONAL PVT. LTD.: PRODUCT PORTFOLIO
TABLE 043. LIFECELL INTERNATIONAL PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. APPLIED BIOLOGICS: SNAPSHOT
TABLE 044. APPLIED BIOLOGICS: BUSINESS PERFORMANCE
TABLE 045. APPLIED BIOLOGICS: PRODUCT PORTFOLIO
TABLE 046. APPLIED BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. LUCINA BIOSCIENCES: SNAPSHOT
TABLE 047. LUCINA BIOSCIENCES: BUSINESS PERFORMANCE
TABLE 048. LUCINA BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 049. LUCINA BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. SKYE BIOLOGICS HOLDINGS LLC: SNAPSHOT
TABLE 050. SKYE BIOLOGICS HOLDINGS LLC: BUSINESS PERFORMANCE
TABLE 051. SKYE BIOLOGICS HOLDINGS LLC: PRODUCT PORTFOLIO
TABLE 052. SKYE BIOLOGICS HOLDINGS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. NUVISION BIOTHERAPIES LIMITED: SNAPSHOT
TABLE 053. NUVISION BIOTHERAPIES LIMITED: BUSINESS PERFORMANCE
TABLE 054. NUVISION BIOTHERAPIES LIMITED: PRODUCT PORTFOLIO
TABLE 055. NUVISION BIOTHERAPIES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. ALLOSOURCE: SNAPSHOT
TABLE 056. ALLOSOURCE: BUSINESS PERFORMANCE
TABLE 057. ALLOSOURCE: PRODUCT PORTFOLIO
TABLE 058. ALLOSOURCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. MIMEDX: SNAPSHOT
TABLE 059. MIMEDX: BUSINESS PERFORMANCE
TABLE 060. MIMEDX: PRODUCT PORTFOLIO
TABLE 061. MIMEDX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. SURGILOGIX: SNAPSHOT
TABLE 062. SURGILOGIX: BUSINESS PERFORMANCE
TABLE 063. SURGILOGIX: PRODUCT PORTFOLIO
TABLE 064. SURGILOGIX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. SMITH & NEPHEW: SNAPSHOT
TABLE 065. SMITH & NEPHEW: BUSINESS PERFORMANCE
TABLE 066. SMITH & NEPHEW: PRODUCT PORTFOLIO
TABLE 067. SMITH & NEPHEW: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. ORGANOGENESIS INC.: SNAPSHOT
TABLE 068. ORGANOGENESIS INC.: BUSINESS PERFORMANCE
TABLE 069. ORGANOGENESIS INC.: PRODUCT PORTFOLIO
TABLE 070. ORGANOGENESIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. INTEGRA LIFESCIENCES CORPORATION: SNAPSHOT
TABLE 071. INTEGRA LIFESCIENCES CORPORATION: BUSINESS PERFORMANCE
TABLE 072. INTEGRA LIFESCIENCES CORPORATION: PRODUCT PORTFOLIO
TABLE 073. INTEGRA LIFESCIENCES CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. STRYKER: SNAPSHOT
TABLE 074. STRYKER: BUSINESS PERFORMANCE
TABLE 075. STRYKER: PRODUCT PORTFOLIO
TABLE 076. STRYKER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. NEXT BIOSCIENCES: SNAPSHOT
TABLE 077. NEXT BIOSCIENCES: BUSINESS PERFORMANCE
TABLE 078. NEXT BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 079. NEXT BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 079. CELULARITY INC.: SNAPSHOT
TABLE 080. CELULARITY INC.: BUSINESS PERFORMANCE
TABLE 081. CELULARITY INC.: PRODUCT PORTFOLIO
TABLE 082. CELULARITY INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 082. NUVISION BIOTHERAPIES LTD.: SNAPSHOT
TABLE 083. NUVISION BIOTHERAPIES LTD.: BUSINESS PERFORMANCE
TABLE 084. NUVISION BIOTHERAPIES LTD.: PRODUCT PORTFOLIO
TABLE 085. NUVISION BIOTHERAPIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 085. KATENA PRODUCTS INC.: SNAPSHOT
TABLE 086. KATENA PRODUCTS INC.: BUSINESS PERFORMANCE
TABLE 087. KATENA PRODUCTS INC.: PRODUCT PORTFOLIO
TABLE 088. KATENA PRODUCTS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 088. SURGENEX: SNAPSHOT
TABLE 089. SURGENEX: BUSINESS PERFORMANCE
TABLE 090. SURGENEX: PRODUCT PORTFOLIO
TABLE 091. SURGENEX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 091. TISSUETECH INC.: SNAPSHOT
TABLE 092. TISSUETECH INC.: BUSINESS PERFORMANCE
TABLE 093. TISSUETECH INC.: PRODUCT PORTFOLIO
TABLE 094. TISSUETECH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 094. VENTRIS MEDICAL LLC: SNAPSHOT
TABLE 095. VENTRIS MEDICAL LLC: BUSINESS PERFORMANCE
TABLE 096. VENTRIS MEDICAL LLC: PRODUCT PORTFOLIO
TABLE 097. VENTRIS MEDICAL LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 097. STIMLABS LLC: SNAPSHOT
TABLE 098. STIMLABS LLC: BUSINESS PERFORMANCE
TABLE 099. STIMLABS LLC: PRODUCT PORTFOLIO
TABLE 100. STIMLABS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 100. VIVEX BIOLOGICS INC: SNAPSHOT
TABLE 101. VIVEX BIOLOGICS INC: BUSINESS PERFORMANCE
TABLE 102. VIVEX BIOLOGICS INC: PRODUCT PORTFOLIO
TABLE 103. VIVEX BIOLOGICS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 103. GENESIS BIOLOGICS: SNAPSHOT
TABLE 104. GENESIS BIOLOGICS: BUSINESS PERFORMANCE
TABLE 105. GENESIS BIOLOGICS: PRODUCT PORTFOLIO
TABLE 106. GENESIS BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106. TIDES MEDICAL: SNAPSHOT
TABLE 107. TIDES MEDICAL: BUSINESS PERFORMANCE
TABLE 108. TIDES MEDICAL: PRODUCT PORTFOLIO
TABLE 109. TIDES MEDICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 109. ORTHOFIX MEDICAL INC.: SNAPSHOT
TABLE 110. ORTHOFIX MEDICAL INC.: BUSINESS PERFORMANCE
TABLE 111. ORTHOFIX MEDICAL INC.: PRODUCT PORTFOLIO
TABLE 112. ORTHOFIX MEDICAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112. MERAKRIS THERAPEUTICS: SNAPSHOT
TABLE 113. MERAKRIS THERAPEUTICS: BUSINESS PERFORMANCE
TABLE 114. MERAKRIS THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 115. MERAKRIS THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115. MTF BIOLOGICS: SNAPSHOT
TABLE 116. MTF BIOLOGICS: BUSINESS PERFORMANCE
TABLE 117. MTF BIOLOGICS: PRODUCT PORTFOLIO
TABLE 118. MTF BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 119. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 120. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 121. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. AMNIOTIC PRODUCTS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. AMNIOTIC PRODUCTS MARKET OVERVIEW BY TYPE
FIGURE 012. AMNIOTIC MEMBRANES {CRYOPRESERVED MARKET OVERVIEW (2016-2028)
FIGURE 013. DEHYDRATED} MARKET OVERVIEW (2016-2028)
FIGURE 014. AMNIOTIC SUSPENSIONS MARKET OVERVIEW (2016-2028)
FIGURE 015. AMNIOTIC PRODUCTS MARKET OVERVIEW BY APPLICATION
FIGURE 016. WOUND CARE MARKET OVERVIEW (2016-2028)
FIGURE 017. OPHTHALMOLOGY MARKET OVERVIEW (2016-2028)
FIGURE 018. ORTHOPEDICS MARKET OVERVIEW (2016-2028)
FIGURE 019. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 020. AMNIOTIC PRODUCTS MARKET OVERVIEW BY END-USER
FIGURE 021. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 022. ASCS MARKET OVERVIEW (2016-2028)
FIGURE 023. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 024. NORTH AMERICA AMNIOTIC PRODUCTS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. EUROPE AMNIOTIC PRODUCTS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. ASIA PACIFIC AMNIOTIC PRODUCTS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. MIDDLE EAST & AFRICA AMNIOTIC PRODUCTS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. SOUTH AMERICA AMNIOTIC PRODUCTS MARKET OVERVIEW BY COUNTRY (2016-2028)
Frequently Asked Questions :
The forecast period in the Amniotic Products Market research report is 2024-2032.
LifeCell International Pvt. Ltd. (India), Applied Biologics (US), Lucina BioSciences (US), Skye Biologics Holdings, LLC (US), Nuvision Biotherapies Limited (UK), AlloSource (US), MiMedx (US), Surgilogix (US), Smith & Nephew (UK), Organogenesis Inc. (US), Integra Lifesciences Corporation (US), Stryker (US), Next Biosciences (South Africa), Celularity, Inc. (the US), NuVision Biotherapies Ltd. (UK), Katena Products, Inc. (US), Surgenex (US), TissueTech, Inc. (the US), Ventris Medical, LLC (US), StimLabs LLC (US), VIVEX Biologics, Inc. (the US), Genesis Biologics (US), Tides Medical (US), Orthofix Medical Inc. (US), Merakris Therapeutics (US), MTF Biologics (US), and Other Major Players.
Amniotic Products Market is segmented into Type, Application, End-User and region. By Type, the market is categorized into Amniotic Membranes {Cryopreserved, Dehydrated}, Amniotic Suspensions. By Application, the market is categorized into Wound Care, Ophthalmology, Orthopedics, Other. By End-User, the market is categorized into Hospitals, ASCs, Others. By region, it is analysed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain, etc.), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
Advancement in regenerative medicine, the Amnio Technology line of products is manufactured from human amniotic membrane and fluid. These amniotic tissues, or allografts, are transplanted to offer protection and support for native tissues in the body.
Global Amniotic Products Market was valued at USD 881.55 Million in 2023 and is expected to reach USD 1580.25 Million by the year 2032, at a CAGR of 6.7%.
